Ki-1—positive lymphoma developing 10 years after the diagnosis of hairy cell leukemia

Abbondanzo, Susan L.; Sulak, Laura E.

doi:10.1002/1097-0142(19910615)67:12<3117::aid-cncr2820671229>3.0.co;2-5

Cited by 8 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…, 1987; Huang et al. , 1987; Abbondanzo & Sulak, 1991; Lopera, Alvarez & Lee, 1995; Nazeer et al. , 1997; Friedline, Crisan & Chen, 1998; Lenz et al.…”

Section: Discussionmentioning

confidence: 99%

Partial remission of a newly diagnosed diffuse large B‐cell non‐Hodgkin's lymphoma in a hemodialysis patient after administration of immuno‐chemotherapy with rituximab‐CHOP

Feldmann¹,

Nattermann²,

Gerhardt³

et al. 2007

Int J Lab Hematology

View full text Add to dashboard Cite

Summary To date little data exist about treatment of hematologic malignancies in patients with end‐stage renal disease (ESRD). While administration of immunochemotherapy comprising the CD20‐antibody rituximab is a well‐established treatment strategy in patients with normal renal function, little information on safety and efficacy is available in the setting of ESRD. Here we describe for the first time a hemodialysis patient suffering from diffuse large B‐cell Non‐Hodgkin's lymphoma (DLBCL) who was treated with polychemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) in combination with rituximab (R‐CHOP). We observed no major adverse events and treatment resulted in a partial remission of the DLBCL. Thus, administration of R‐CHOP may be considered as a safe therapeutic option in this setting. Of note, this patient had a previous history of hairy cell leukemia. A review of the literature was performed and the potential etiologic link of these two B‐cell malignancies is discussed in the light of available information.

show abstract

“…, 1987; Huang et al. , 1987; Abbondanzo & Sulak, 1991; Lopera, Alvarez & Lee, 1995; Nazeer et al. , 1997; Friedline, Crisan & Chen, 1998; Lenz et al.…”

Section: Discussionmentioning

confidence: 99%

Partial remission of a newly diagnosed diffuse large B‐cell non‐Hodgkin's lymphoma in a hemodialysis patient after administration of immuno‐chemotherapy with rituximab‐CHOP

Feldmann¹,

Nattermann²,

Gerhardt³

et al. 2007

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…8 This pair of markers is considered relatively specific for HCL, but can also be seen in other tumors. 1 Nevertheless, in this case HCL cells were not studied by flow cytometry; thus there was no direct evidence that these 2 groups of tumor cells shared the same immunophenotype (CD11cϩ, CD22ϩ).…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6] Three studies provided circumstantial evidence. [7][8][9] Only 2 cases were well documented with immunophenotyping and molecular genetic studies, but opposite conclusions were drawn in terms of the clonal relationship between these 2 tumors. 10, 11 The present report documents a case of HCL that transformed to a high-grade large cell lymphoma.…”

mentioning

confidence: 99%

Transformation of hairy cell leukemia to high-grade lymphoma: A case report and review of the literature

2004

View full text Add to dashboard Cite

Current Clinical Practice: Treatment of Hairy Cell Leukemia at the Close of the 20th Century

Kreitman

Cheson

1999

Hematology

View full text Add to dashboard Cite

In the last half of this century, hairy cell leukemia was recognized as a distinct B-cell malignancy, accounting for 2% of all leukemias. Characteristics include splenomegaly, pancytopenia, a usually indolent course, and responsiveness to both interferon and purine analog therapy. Accurate diagnosis requires the demonstration of malignant cells in the bone marrow and peripheral blood which contain cytoplasmic projections and characteristic surface antigens. Splenectomy was identified early as a palliative therapy, and in 1984 systemic treatment with interferon alpha was first reported to induce complete remissions. Soon thereafter, the purine analog deoxycoformycin was found to induce more durable complete remissions in a higher percentage of patients. In 1990, 2-Chlorodeoxyadenosine, a new purine analog therapy, was reported to be capable of inducing long-term durable responses in most patients after a single cycle. Current challenges include identifying which purine analog is the least toxic since both appear similarly effective, and neither appear to add to the already increased rate of second malignancies occurring in these patients. Moreover, up to 25% of patients with hairy cell leukemia fail initially or eventually to respond to standard therapy, making the development of new approaches necessary. The characteristic bright expression of several B-cell antigens on the malignant cells, including CD20, CD22 and CD25, has led to the development of targeted biotherapeutic approaches. A recombinant immunotoxin targeting CD25 has recently been reported to induce major responses and it is likely that other successful targeted approaches will be reported early in the new century.

show abstract

Ki-1—positive lymphoma developing 10 years after the diagnosis of hairy cell leukemia

Cited by 8 publications

References 34 publications

Partial remission of a newly diagnosed diffuse large B‐cell non‐Hodgkin's lymphoma in a hemodialysis patient after administration of immuno‐chemotherapy with rituximab‐CHOP

Partial remission of a newly diagnosed diffuse large B‐cell non‐Hodgkin's lymphoma in a hemodialysis patient after administration of immuno‐chemotherapy with rituximab‐CHOP

Transformation of hairy cell leukemia to high-grade lymphoma: A case report and review of the literature

Current Clinical Practice: Treatment of Hairy Cell Leukemia at the Close of the 20th Century

Contact Info

Product

Resources

About